Promising Medical Stocks To Follow Now - November 19th

Danaher logo with Healthcare background
Image from MarketBeat Media, LLC.

Danaher, Humana, and Gilead Sciences are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. “Medical stocks” are shares of companies involved in healthcare, such as pharmaceutical and biotech firms, medical-device makers, and healthcare providers. Investors may buy them to gain exposure to healthcare demand and innovation, though their performance can be affected by factors such as regulation, clinical-trial results, and patent changes. These companies had the highest dollar trading volume of any Medical stocks within the last several days.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

DHR stock traded down $0.66 on Thursday, reaching $227.92. The company's stock had a trading volume of 1,685,985 shares, compared to its average volume of 4,398,661. Danaher has a 52 week low of $160.93 and a 52 week high of $242.80. The company has a market capitalization of $160.35 billion, a P/E ratio of 37.47, a price-to-earnings-growth ratio of 2.84 and a beta of 0.76. The firm has a fifty day moving average of $223.88 and a two-hundred day moving average of $201.62. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.63 and a quick ratio of 1.29.

Read Our Latest Research Report on DHR

Humana (HUM)

Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

NYSE HUM traded down $7.92 on Thursday, hitting $377.86. 816,332 shares of the company were exchanged, compared to its average volume of 1,659,935. The company's 50 day moving average price is $410.26 and its 200-day moving average price is $320.44. Humana has a twelve month low of $163.11 and a twelve month high of $462.87. The firm has a market capitalization of $45.38 billion, a P/E ratio of 36.74, a price-to-earnings-growth ratio of 2.11 and a beta of 0.65. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.65 and a quick ratio of 1.65.

Read Our Latest Research Report on HUM

Gilead Sciences (GILD)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Shares of Gilead Sciences stock traded down $1.65 during trading on Thursday, hitting $167.33. 1,538,324 shares of the stock traded hands, compared to its average volume of 6,755,504. The company has a fifty day moving average price of $156.37 and a two-hundred day moving average price of $142.23. Gilead Sciences has a twelve month low of $116.88 and a twelve month high of $176.58. The stock has a market cap of $207.54 billion, a P/E ratio of -52.96 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38.

Read Our Latest Research Report on GILD

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines